There are currently 348 studies (as of July 4, 2022) for hydroxychloroquine as a treatment for COVID-19. The drug is 92% effective as an early treatment, 67% effective as a late treatment, and 83% effective as a pre and post-exposure prophylaxis.
See the data here. More data here.
Dr. Stella Immanuel demands an apology after studies prove she was right about Hydroxychloroquine
Lancet study that found hydroxychloroquine harmful in treating COVID-19 has been retracted.
The study “found that the use of a regimen containing hydroxychloroquine or chloroquine (with or without a macrolide) was associated with no evidence of benefit, but instead was associated with an increase in the risk of ventricular arrhythmias and a greater hazard for in-hospital death with COVID-19. These findings suggest that these drug regimens should not be used outside of clinical trials and urgent confirmation from randomised clinical trials is needed.” See the retracted study here and here.
Dr. Frank Ruschitka is one of the researchers who conducted this study. He works for University Heart Center at University Hospital Zurich, Switzerland. The acknowledgements say that Dr. Ruschitka received “grants and personal fees from SJM/Abbott, grants and personal fees from Servier, personal fees from Zoll, personal fees from Astra Zeneca, personal fees from Sanofi, grants and personal fees from Novartis, personal fees from Amgen, personal fees from BMS, personal fees from Pfizer, personal fees from Fresenius, personal fees from Vifor, personal fees from Roche, grants and personal fees from Bayer, personal fees from Cardiorentis, personal fees from Boehringer Ingelheim, other from Heartware, and grants from Mars.” Emphasis added.
Dr. Anthony Cardillo explains how hydroxychloroquine paired with zinc kills COVID-19
Second-largest factory in the world that produces hydroxychloroquine precursors goes up in flames (December 20, 2020)
HELP US FIGHT CENSORSHIP. DONATE TODAY.